Loading organizations...
§ Private Profile · Hangzhou, Zhejiang, China
clinical-stage biopharmaceutical company discovering and developing multi-specific biotherapeutics for metabolic diseases and cancers.
Doer Biologics is a clinical-stage biopharmaceutical company based in Hangzhou, Zhejiang, China, that discovers and develops multi-specific biotherapeutics for metabolic diseases and cancers. The organization leverages proprietary engineering platforms, including xLONGylation, MultiBody, AccuBody, and SMART-VHHBody, to create nanobodies and trispecific antibodies targeting severe unmet medical needs across global patient populations. Its clinical pipeline features several active programs, such as the DR10624 candidate, which successfully dosed its first patient in a Phase 2 study for severe hypertriglyceridemia during September 2024. Additionally, the firm is advancing Phase 1 clinical trials for DR10628 and DR10627, which are designed to target obesity through combined GLP-1R and GIPR agonist mechanisms. Operating as a subsidiary, the enterprise was acquired through a majority stake purchase by the pharmaceutical corporation Huadong Medicine in April 2021. Doer Biologics was founded in 2014.
Doer Biologics has raised $14.9M across 1 funding round.
Doer Biologics has raised $14.9M in total across 1 funding round.
Doer Biologics has raised $14.9M in total across 1 funding round.
Doer Biologics's investors include Kaitai Capital.
Doer Biologics has raised $14.9M across 1 funding round. Most recently, it raised $14.9M Series A in November 2020.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 2, 2020 | $14.9M Series A | — | Kaitai Capital | Announced |